Analysis of Effectiveness, Safety, and Bleeding Related to Rivaroxaban in Elderly Patients

• Published in: Clinical and applied thrombosis/hemostasis 2020, Vol.26, p.1076029620925923
• Main Authors: Hou, Huimin, Li, Ang, Zhang, Liping, Qin, Xiujiao, Jiang, Yanfang, Zhao, Huiying
• Format: Article
• Language: English
• Subjects: Age; Aged; Aged, 80 and over; Female; Humans; Male; Middle Aged; Original; Retrospective Studies; Rivaroxaban - adverse effects; Rivaroxaban - pharmacology; Rivaroxaban - therapeutic use
• ISSN: 1076-0296; 1938-2723
• DOI: 10.1177/1076029620925923

This study explored the efficacy and safety of rivaroxaban in elderly patients, at different doses and age of patients, and analyzed risk factors of bleeding. A retrospective analysis was conducted of 299 patients aged 60 years or older who were admitted to the First Hospital of Jilin University between January 2016 and August 2018. It was found that the rate of bleeding events (but not embolism) significantly increased as the dose of oral rivaroxaban increased (P < .001), and with age, especially in patients aged ≥80 years (P = .001, both). The multivariate logistic regression analysis indicated that age (odds ratio [OR]: 2.963, 95% CI: 1.627-5.396) and the daily dose of rivaroxaban (OR: 2.325, 95% CI: 1.483-3.645) were independent risk factors for bleeding. The study determined that rivaroxaban anticoagulant therapy is effective in the elderly patients, but the risk of bleeding increases with age, and is a concern especially in the most old patients. The recommended daily dose of rivaroxaban is effective, but a lower dose is safer for the elderly patients.